Literature DB >> 15930183

Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.

Liat Abovich Gilad1, Tali Bresler, Julia Gnainsky, Patricia Smirnoff, Betty Schwartz.   

Abstract

We previously demonstrated that 17beta-estradiol (E2) regulates the transcription and expression of the vitamin D receptor (VDR) in rat colonocytes and duodenocytes in vivo. The aim of the present study was to assess whether the extracellular signal-regulated kinase (ERK) induced by E2 is involved in regulating VDR expression. We compared E2-associated signaling activity in HT29 colon cancer cells, a non-classical E2-target, with that in MCF-7 breast cancer cells, the natural targets of the hormone. E2 did not affect proliferation of HT29 cells, but enhanced proliferation of MCF-7 cells. Vitamin D inhibited proliferation of both cell lines and the combined treatment induced potentiation of vitamin D activity. E2 upregulated VDR transcription and protein expression concomitantly with ERK 1/2 phosphorylation in both cell lines. PD98059, a specific mitogen-activated protein kinase (MAPK) inhibitor, prevented E2-mediated activation of ERK 1/2, with concomitant inhibition of VDR expression. ICI182780 inhibited VDR expression in HT29 and MCF-7 cell lines. A conjugate of E2 and bovine serum albumin upregulated phosphorylation of ERK 1/2 and concomitantly enhanced VDR expression in a similar fashion as the nonconjugated hormone. Expression of ERalpha and ERbeta was detected in MCF-7 and HT29 cell lines respectively, which localized to the nuclei, cytosol and caveolar membrane rather than non-caveolar membrane. Disruption of lipid rafts/caveolae by depleting cellular cholesterol with the cholesterol-binding reagent beta-methylcyclodextrin blocked ERK 1/2 phosphorylation concomitantly with VDR upregulation. The tyrosine phosphorylation inhibitor suramin and src kinase inhibitor PP2 inhibited both ERK 1/2 phosphorylation and VDR expression. E2 induced phosphorylation of Raf and Jun in a time-dependent manner. The Ras/Raf dependent inhibitor of transactivation sulindac sulfide also blocked E2 effects. The specific c-Jun phosphorylation inhibitor SP600125 dose dependently inhibited c-Jun phosphorylation and VDR expression. The MAPK/ERK kinase inhibitor PD 98059 downregulated both c-Jun phosphorylation and VDR expression indicating that upstream and downstream events in the signaling cascade are all related to the control of VDR expression. Taken together, our data suggest that E2 binds to receptors compartmentalized to membranal caveolar domains in HT29 and MCF-7 cells, inducing ERK 1/2 activation and transcriptional activity, which finally results in upregulation of expression of the VDR gene.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15930183     DOI: 10.1677/joe.1.05770

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  25 in total

Review 1.  Estrogen-TGFbeta cross-talk in bone and other cell types: role of TIEG, Runx2, and other transcription factors.

Authors:  J R Hawse; M Subramaniam; J N Ingle; M J Oursler; N M Rajamannan; T C Spelsberg
Journal:  J Cell Biochem       Date:  2008-02-01       Impact factor: 4.429

2.  Tumor Expression of Vitamin D Receptor and Breast Cancer Histopathological Characteristics and Prognosis.

Authors:  Jamila Al-Azhri; Yali Zhang; Wiam Bshara; Gary Zirpoli; Susan E McCann; Thaer Khoury; Carl D Morrison; Stephen B Edge; Christine B Ambrosone; Song Yao
Journal:  Clin Cancer Res       Date:  2016-07-12       Impact factor: 12.531

3.  How I treat vitamin d deficiency.

Authors:  Qamar J Khan; Carol J Fabian
Journal:  J Oncol Pract       Date:  2010-03       Impact factor: 3.840

4.  Genetic variation in sex-steroid receptors and synthesizing enzymes and colorectal cancer risk in women.

Authors:  Jennifer Lin; Robert Y L Zee; Kuang-Yu Liu; Shumin M Zhang; I-Min Lee; JoAnn E Manson; Edward Giovannucci; Julie E Buring; Nancy R Cook
Journal:  Cancer Causes Control       Date:  2010-02-11       Impact factor: 2.506

Review 5.  Vitamin D and breast cancer.

Authors:  Theresa Shao; Paula Klein; Michael L Grossbard
Journal:  Oncologist       Date:  2012-01-10

6.  Vitamin D receptor and enzyme expression in dorsal root ganglia of adult female rats: modulation by ovarian hormones.

Authors:  Sarah E Tague; Peter G Smith
Journal:  J Chem Neuroanat       Date:  2010-10-20       Impact factor: 3.052

7.  Musculoskeletal adverse events associated with adjuvant aromatase inhibitors.

Authors:  Qamar J Khan; Anne P O'Dea; Priyanka Sharma
Journal:  J Oncol       Date:  2010-08-24       Impact factor: 4.375

8.  CYP24A1 inhibition facilitates the anti-tumor effect of vitamin D3 on colorectal cancer cells.

Authors:  János P Kósa; Péter Horváth; János Wölfling; Dóra Kovács; Bernadett Balla; Péter Mátyus; Evelin Horváth; Gábor Speer; István Takács; Zsolt Nagy; Henrik Horváth; Péter Lakatos
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

9.  Harnessing competing endocytic pathways for overcoming the tumor-blood barrier: magnetic resonance imaging and near-infrared imaging of bifunctional contrast media.

Authors:  Helena Sheikhet Migalovich; Vyacheslav Kalchenko; Nava Nevo; Gila Meir; Fortune Kohen; Michal Neeman
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

Review 10.  Epithelial Barrier Function in Gut-Bone Signaling.

Authors:  Naiomy Deliz Rios-Arce; Fraser L Collins; Jonathan D Schepper; Michael D Steury; Sandi Raehtz; Heather Mallin; Danny T Schoenherr; Narayanan Parameswaran; Laura R McCabe
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.